scientific advisory board

Professor Martin Koltzenburg

Professor Martin Koltzenburg is a neurologist and the Head of the Department of Clinical Neurophysiology at The National Hospital for Neurology and Neurosurgery at Queen Square. He studied medicine at the University of Kiel, Germany and UCL during this time he earned a doctorate with research into the neurophysiological mechanisms of pain. This was followed by postdoctoral research and clinical specialist training at the Department of Physiology of the University of Erlangen, the Department of Neurology of the University of Würzburg, Germany and the Department of Clinical Neurophysiology of the University of Uppsala, Sweden. Martin shares his time between the clinic and research laboratory. His clinical work focuses on neurophysiological techniques in the assessments of neuromuscular disorders including neuropathic pain and translational methods in drug discovery. His basic science team investigates the properties of sensory neurons on a cellular and system level, particularly the mechanisms of neurodegeneration leading to peripheral neuropathy. He has been awarded the Research Prize of the International Association for the Study of Pain, and the Patrick Wall Medal of the British Pain Society. He has published over 100 peer reviewed original articles in clinical and basic science. He is on the editorial board of the Journal of Pain, Nature Reviews in Neurology and Faculty 1000 Medicine and has edited several books including Wall and Melzack’s Textbook of Pain, the standard text of the field.

Professor Maria Belvisi

Professor Maria Belvisi is Head of the Respiratory Pharmacology group at the National Heart and Lung Institute at Imperial College. Professor Belvisi is an internationally recognized expert in the respiratory field with both academic and industrial experience. Her research is focused on the cellular and molecular mechanisms of asthma, COPD and chronic cough and developing therapies for these diseases. She is involved in multidisciplinary translational research which integrates basic science with clinical studies, thereby providing novel insights into common airway diseases. She also worked for a period in the pharmaceutical industry leading a team in the Respiratory Therapeutic area at Aventis Pharma. Her achievements in industry included running the pre-clinical pharmacology effort in support of an inhaled corticosteroid with an improved therapeutic ratio (ciclesonide/Alvesco), which is now approved for use in man in several countries. Professor Belvisi has an extensive publication record in peer review journals and serves on the Editorial Board of several journals.

Dr Mark Birrell

Dr Mark Birrell is a Research lecturer in the Respiratory Pharmacology Research Group at the National Heart and Lung Institute at Imperial College. Mark obtained a BSc (Hons) Degree in Pharmacology from the University of East London whilst working at a major pharmaceutical company, Sanofi-Aventis. During his 15 years in industry Mark has had extensive experience in various phases of drug discovery. The therapeutic aim was to develop new medicine for initially cardiovascular diseases and then later respiratory diseases. Mark has a substantial publication record in peer review journals and is an internationally recognised expert in the respiratory field, particularly in pre-clinical models of asthma and COPD.